Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2024
Piramal Pharma Q4 Results Review - Solid Quarter; Grim Near-Term Outlook: ICICI Securities
Contract development manufacturing organisation outlook intact, investment in complex hospital generics business on rise
In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal
Nandini Piramal projects early teens revenue growth for FY25 and 22-25% EBITDA growth margins in 3-5 years. Revenue increase drives margin expansion through cost optimization and operational excellence, with a focus on CDMO and Indian consumer products growth. On-patent and differentiated offerings will give Piramal Pharma an edge, says Chairperson
The strategy is to stay the course and grow CDM and consumer healthcare businesses Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2024 Q4FY24 Quarterly & FY24 Annual Result Announced for Piramal Pharma Ltd.
Pharmaceuticals company Piramal Pharma announced Q4FY24 & FY24 results: Revenue from Operations grew by 18% YoY and 15% YoY in Q4FY24 and FY24 respectively, driven by healthy growth in our CDMO and ICH businesses EBITDA grew by 48% YoY and 61% YoY in Q4FY24 and FY24 respectively, primarily driven by revenue growth, operating leverage, cost optimization, and operational excellence initiatives Net Profit After Tax (before exceptional Items) more than doubled in Q4FY24 at Rs 132 crore compared to Rs 50 crore in Q4FY23 Net Debt / EBITDA improved from 5.6x at the start of the financial year to 2.9x at the end of FY24 Nandini Piramal, Chairperson, Piramal Pharma Limited said, “FY24 has been a strong year for the Company with all round improvement, mainly driven by our CDMO business that delivered a robust 19% YoY revenue growth. We saw significant increase in order inflows, especially for on-patent commercial manufacturing, amidst a difficult biotech funding environment. Contributions from our innovation related work and differentiated offerings also increased in FY24. Capacity expansion at our Grangemouth facility for Antibody Drug Conjugate segment was commercialized and is seeing good customer interest. In the Inhalation anesthesia business, we continue to maintain our leading position in Sevoflurane in the US market and are expanding our capacities to tap the growing demand in the ROW markets. Our India Consumer Healthcare business is also continuing to perform well with focus on better EBITDA margin. During the year, we also showed a significant improvement in our profitability with EBITDA margin of 17% (Vs. 12% in FY23). All our three businesses delivered higher EBITDA margins through operating leverage, cost optimization, and operational excellence initiatives. Our Net Debt / EBITDA ratio also improved significantly, as we ended the financial year below 3x compared to 5.6x at the start of the year.” Result PDF
Piramal Pharma Results Earnings Call for Q4FY24
Conference Call with Piramal Pharma Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Piramal Pharma Q4 Results: Profit Rises, But Misses Estimates
Net profit of the company rose two times YoY to Rs 101.27 crore in the fourth quarter, as compared with Rs 50.11 crore in the year-ago period. Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Change in Directorate
Resignation of Ms. Nathalie Leitch as Non-Executive, Non-Independent Director.